As US medtech heavyweights pour billions into bladder-control therapies for ageing populations, an Australian company is ...

SPR will feature eight abstracts on 60-day peripheral nerve stimulation (PNS) with SPRINT® PNS that will be presented at the ...

ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced a landmark clinical research collaboration to evaluate precision radiomodulation therapy for ...

Archana Puran Singh’s CRPS diagnosis highlights a rare, life-altering pain disorder. Here’s what Complex Regional Pain ...

For decades, restoring sight after severe eye damage sat firmly in the realm of science fiction. Now a wave of converging advances, from gene editing and stem cells to microchips and laser-based ...

In severe treatment-resistant depression, long-term data show VNS benefits not only persist for 2 years but also continue to emerge in late responders.

Craniofacial pain is among the most common chronic pain conditions, affecting more than one-fifth of the U.S. population 1. With this milestone, Curonix advances its mission to drive full-body PNS ...

About 20% of U.S. adults experience major depression in their lifetime. For most people, symptoms improve within a few treatment attempts, but up to one-third of patients have treatment-resistant ...

Phagenesis, a commercial-stage company with a first-of-its-kind neuromodulation system to treat patients experiencing difficulty swallowing post-stroke, welcomed the 2026 Guideline for the Early ...

A large multicenter clinical trial led by King's College London with 150 children and adolescents has shown that a device cleared by the US FDA to treat ADHD is not effective in reducing symptoms.